DGAP-News: aap Implantate AG / Key word(s): Personnel
04.07.2019 / 14:52
The issuer is solely responsible for the content of this announcement.
aap Implantate AG (“aap“) announces that the members of the company’s Supervisory Board have elected Ms. Dr. med. Nathalie Krebs (47) as their new Chairwoman. Before, Ms. Dr. med. Krebs was elected to the Supervisory Board of the company by aap‘s Annual General Meeting held on 21 June 2019 in Berlin with an overwhelming majority (99.99%). Her election is effective from the end of the Annual General Meeting on 21 June 2019 until the end of the Annual General Meeting that resolves on the discharge of the Supervisory Board for the financial year 2021.
“In Ms. Dr. med. Krebs we are delighted to have gained a proven expert in medicine and business as well as a strong personality for aap‘s Supervisory Board”, says Biense Visser, member and previous Chairman of the Supervisory Board at aap. “She looks back on many years of experience in the fields of pharmaceuticals, medical technology and consulting and is additionally active in other Supervisory Bodies of business enterprises with a medical alignment. We are very much looking forward to the cooperation and are firmly convinced that aap will benefit from her comprehensive expertise.”
Ms. Dr. med. Krebs is a graduated doctor and studied and graduated at University Basel, Switzerland. She is currently a member of the Board of Directors at several companies and has extensive experience based on different responsible positions in the pharmaceutical industry, in medical technology and with consulting companies, such as Bayer and Boston Consulting Group.
About aap Implantate AG
For inquiries please contact:
aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; 12099 Berlin, Germany; Tel.: +49/30/750 19 – 134; Fax.: +49/30/750 19 – 290; firstname.lastname@example.org
04.07.2019 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Company:||aap Implantate AG|
|Phone:||+49 (0) 30 75 01 90|
|Fax:||+49 (0) 30 75 01 91 11|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||836365|
|End of News||DGAP News Service|